BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27462863)

  • 1. Structural basis for exploring the allosteric inhibition of human kidney type glutaminase.
    Ramachandran S; Pan CQ; Zimmermann SC; Duvall B; Tsukamoto T; Low BC; Sivaraman J
    Oncotarget; 2016 Sep; 7(36):57943-57954. PubMed ID: 27462863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
    Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
    J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism.
    Thangavelu K; Pan CQ; Karlberg T; Balaji G; Uttamchandani M; Suresh V; Schüler H; Low BC; Sivaraman J
    Proc Natl Acad Sci U S A; 2012 May; 109(20):7705-10. PubMed ID: 22538822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BPTES inhibition of hGA(124-551), a truncated form of human kidney-type glutaminase.
    Hartwick EW; Curthoys NP
    J Enzyme Inhib Med Chem; 2012 Dec; 27(6):861-7. PubMed ID: 21999665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators.
    Stalnecker CA; Erickson JW; Cerione RA
    J Biol Chem; 2017 Apr; 292(15):6095-6107. PubMed ID: 28196863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full-length human glutaminase in complex with an allosteric inhibitor.
    DeLaBarre B; Gross S; Fang C; Gao Y; Jha A; Jiang F; Song J J; Wei W; Hurov JB
    Biochemistry; 2011 Dec; 50(50):10764-70. PubMed ID: 22049910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase.
    Zimmermann SC; Duvall B; Tsukamoto T
    J Med Chem; 2019 Jan; 62(1):46-59. PubMed ID: 29969024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES).
    Robinson MM; McBryant SJ; Tsukamoto T; Rojas C; Ferraris DV; Hamilton SK; Hansen JC; Curthoys NP
    Biochem J; 2007 Sep; 406(3):407-14. PubMed ID: 17581113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
    Elgogary A; Xu Q; Poore B; Alt J; Zimmermann SC; Zhao L; Fu J; Chen B; Xia S; Liu Y; Neisser M; Nguyen C; Lee R; Park JK; Reyes J; Hartung T; Rojas C; Rais R; Tsukamoto T; Semenza GL; Hanes J; Slusher BS; Le A
    Proc Natl Acad Sci U S A; 2016 Sep; 113(36):E5328-36. PubMed ID: 27559084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Development of Small Molecule Glutaminase Inhibitors.
    Song M; Kim SH; Im CY; Hwang HJ
    Curr Top Med Chem; 2018; 18(6):432-443. PubMed ID: 29793408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
    Masamha CP; LaFontaine P
    J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors.
    Shukla K; Ferraris DV; Thomas AG; Stathis M; Duvall B; Delahanty G; Alt J; Rais R; Rojas C; Gao P; Xiang Y; Dang CV; Slusher BS; Tsukamoto T
    J Med Chem; 2012 Dec; 55(23):10551-63. PubMed ID: 23151085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the molecular mechanisms of glutaminase C inhibitors in cancer cells using serial room temperature crystallography.
    Milano SK; Huang Q; Nguyen TT; Ramachandran S; Finke A; Kriksunov I; Schuller DJ; Szebenyi DM; Arenholz E; McDermott LA; Sukumar N; Cerione RA; Katt WP
    J Biol Chem; 2022 Feb; 298(2):101535. PubMed ID: 34954143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activation loop and substrate-binding cleft of glutaminase C are allosterically coupled.
    Li Y; Ramachandran S; Nguyen TT; Stalnecker CA; Cerione RA; Erickson JW
    J Biol Chem; 2020 Jan; 295(5):1328-1337. PubMed ID: 31871054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors.
    Thomas AG; Rojas C; Tanega C; Shen M; Simeonov A; Boxer MB; Auld DS; Ferraris DV; Tsukamoto T; Slusher BS
    Biochem Biophys Res Commun; 2013 Aug; 438(2):243-8. PubMed ID: 23850693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric kidney-type glutaminase (GLS) inhibitors with a mercaptoethyl linker.
    Duvall B; Zimmermann SC; Gao RD; Thomas AG; Kalčic F; Veeravalli V; Elgogary A; Rais R; Rojas C; Le A; Slusher BS; Tsukamoto T
    Bioorg Med Chem; 2020 Oct; 28(20):115698. PubMed ID: 33069080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA).
    Thangavelu K; Chong QY; Low BC; Sivaraman J
    Sci Rep; 2014 Jan; 4():3827. PubMed ID: 24451979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
    Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
    BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
    Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
    Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lysine to alanine mutations on the phosphate activation and BPTES inhibition of glutaminase.
    McDonald CJ; Acheff E; Kennedy R; Taylor L; Curthoys NP
    Neurochem Int; 2015 Sep; 88():10-4. PubMed ID: 25510640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.